Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance

European Respiratory Journal

Volumn 43, Issue 2, 2014, Pages 566-581

  Law, Stephanie ^a   Benedetti, Andrea ^a   Oxlade, Olivia ^a   Schwartzman, Kevin ^a   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLINDNESS; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG RESISTANCE, BACTERIAL; ETHAMBUTOL; HEALTH CARE COSTS; HUMANS; ISONIAZID; MARKOV CHAINS; PREVALENCE; PROBABILITY; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 84893470261     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00005613     Document Type: Article

References (61)

1. World Health Organization. Global Tuberculosis Report 2012. www.who.int/tb/publications/global-report/en/index.html Date last accessed: August 17, 2013.
2. World Health Organization. Anti-Tuberculosis Drug Resistance in the World: Fourth Global Report. Report number WHO/HTM/TB/2008.39 http://whqlibdoc.who.int/hq/2008/WHO-HTM-TB-2008.394-eng.pdf Date last accessed: August 17, 2013.
3. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6: 1-14.
4. Lew W, Pai M, Oxlade O, et al. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008; 149: 123-134.
5. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO progress report 2011. www.who.int/tb/publications/2011/mdr-report- 2011/en/ Date last accessed: August 17, 2013.
6. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
7. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 4th Edn. Report number WHO/HTM/TB/2009.420. www.who.int/tb/publications/tb-treatmentguidelines/en/ Date last accessed: August 17, 2013.
8. Kim Y, Suh G, Chung M, et al. Treatment of isoniazid-resistant pulmonary tuberculosis. BMC Infect Dis 2008; 8: 6.
9. Koh W, Kwon O, Park Y, et al. Development of multidrug resistance during treatment of isoniazid-resistant tuberculosis. Eur Respir J 2005; 26: 557.
10. Chatterjee V, Buchanan D, Friedmann A, et al. Ocular toxicity following ethambutol in standard dosage. Br J Dis Chest 1986; 80: 288-291.
11. Harcombe A, Kinnear W, Britton J, et al. Ocular toxicity of ethambutol. Respir Med 1991; 85: 151-153.
12. Kahana L. Toxic ocular effects of ethambutol. CMAJ 1987; 137: 213-216.
13. Leibold J. The ocular toxicity of ethambutol and its relation to dose. Ann NY Acad Sci 1966; 135: 904-909.
14. Ezer N, Benedetti A, Darvish-Zargar M, et al. Incidence of ethambutol-related visual impairment during treatment of active tuberculosis. Int J Tuberc Lung Dis 2013; 17: 447-455.
15. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
16. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-1258.
17. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes, Oxford: Oxford University Press, 2005.
18. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50: 1288-1299.
19. Baltussen R, Floyd K, Dye C. Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ 2005; 331: 1364.
20. Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 2003; 326: 574.
21. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196: Suppl. 1, S86-S107.
22. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-651.
23. Mokaddas E, Ahmad S, Samir I. Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996-2005. Int J Tuberc Lung Dis 2008; 12: 319-325.
24. Van Rie A, Warren R, Mshanga I, et al. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J Clin Microbiol 2001; 39: 636-641.
25. Siddiqi N, Shamim M, Hussain S, et al. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India. Antimicrob Agents Chemother 2002; 46: 443-450.
26. Afanas'ev MV, Ikryannikova LN, Il'ina EN, et al. Molecular characteristics of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates from the Russian Federation. J Antimicrob Chemother 2007; 59: 1057-1064.
27. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. Report number WHO/HTM/TB/2009.411. www.who.int/tb/publications/global-report/2009/en/ Date last accessed: August 17, 2013.
28. Rieder HL. Epidemiologic Basis of Tuberculosis Control, Paris: International Union Against Tuberculosis and Lung Disease, 1999.
29. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4: e6914.
30. World Health Organization. Global Health Observatory Data Repository - Life expectancy: Life Tables Ecuador. Geneva, WHO, 2009. http://apps.who.int/ gho/data/view.main.60490?lang5en. Date last accessed: August 17, 2013.
31. Remme JHF. The Global Burden of Onchocerciasis in 1990, Geneva: World Health Organization, 2004.
32. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000146.
33. Grzybowski S, Enarson DA. The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc 1978; 53: 70-74.
34. Chee CBE, Boudville IC, Chan SP, et al. Patient and disease characteristics, and outcome of treatment defaulters from the Singapore TB control unit-a one-year retrospective survey. Int J Tuberc Lung Dis 2000; 4: 496-503.
35. Cummings KC, Mohle-Boetani J, Royce S, et al. Movement of tuberculosis patients and the failure to complete antituberculosis treatment. Am J Respir Crit Care Med 1998; 157: 1249-1252.
36. Murray CJL, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020, Cambridge: Harvard University Press, 1996.
37. Van Deun A, Salim MAH, Das APK, et al. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8: 560-567.
38. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006; 12: 1389-1397.
39. Tupasi TE, Gupta R, Quelapio MID, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006; 3: e352.
40. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-280.
41. Heston A, Summers R, Aten B. Penn World Table Version 6.3, Center for International Comparisons of Production, Income and Prices at the University of Pennsylvania, August 2009. http://pwt.econ.upenn.edu/ php-site/pwt-index.php Date last accessed: August 17, 2013.
42. US Dept. of Labor Bureau of Labor Statistics. Consumer Price Index - All Urban Consumers (CPI - U). ftp://ftp.bls. gov/pub/special.requests/cpi/cpiai.txt Date last accessed: August 17, 2013.
43. Rouzier VA, Oxlade O, Verduga R, et al. Patient and family costs associated with tuberculosis, including multidrug resistant tuberculosis in Ecuador. Int J Tuberc Lung Dis 2010; 14: 1316-1322.
44. World Bank. World Development Indicators database, Washington, DC: World Bank, 2010.
45. Vaca J, Peralta H, Gresely L, et al. DOTS implementation in a middle-income country: development and evaluation of a novel approach. Int J Tuberc Lung Dis 2005; 9: 521-527.
46. The Global Fund. Expansion of DOTS Strategy in Ecuador, Geneva, The Global Fund to FIght AIDS, Tuberculosis and Malaria, 2011.
47. Tabla de remuneración salarial 2010. [Table of Salary and Remunerations 2010]. Correos del Ecuador CDE E.P. www.correosdelecuador.com.ec/- upload/TABLA%20DE%20REMUNERACI%C3%93N%20SALARIAL%202010.pdf Date last accessed: December 5, 2013.
48. Deficiencias en los hospitales son nacionales [National deficiencies in the hospitals]. Ecuadorinmediato.com. www.ecuadorinmediato.com/index.php? module5Noticias&func5news-user-view&id535229&umt5expreso-guayaquil- deficiencias-en-hospitales-son-nacionales Date last accessed: December 5, 2013.
49. Emergencia en el hospital delfina torres de conha. [Emergency in the Hospital Delfina Torres de Concha]. August 16, 1998. www.explored.com.ec/ noticias-ecuador/emergencia-en-el-hospital-delfina-torres-de-conha-95071-95071. html Date last accessed: August 17, 2013.
50. Aspler A, Menzies D, Oxlade O, et al. Cost of tuberculosis diagnosis and treatment from the patient perspective in Lusaka, Zambia. Int J Tuberc Lung Dis 2008; 12: 928-935.
51. Jacquet V, Morose W, Schwartzman K, et al. Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti. BMC Public Health 2006; 6: 209.
52. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479-500.
53. Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
54. Murray CJL, Salomon JL. Expanding the WHO tuberculosis control strategy: rethinking the role of active casefinding. Int J Tuberc Lung Dis 1998; 2: S9-S15.
55. Shepard DS, Agness-Soumahoro J, Bail RN, et al. Expenditures on HIV/AIDS: levels and determinants lessons from five countries. AIDS and Development: the role of government, . Limelette: , World Bank, European Union & UNAIDS, 1996.
56. Floyd K, Hutubessy R, Kliiman K, et al. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Eur Respir J 2012; 40: 133-142.
57. Guo N, Marra F, Marra CA. Measuring health-related quality of life in tuberculosis: a systematic review. Health Qual Life Outcomes 2009; 7: 14.
58. Mallory KF, Churchyard GJ, Kleinschmidt I, et al. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2000; 4: 455-462.
59. Khan A, Sterling TR, Reves R, et al. Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med 2006; 174: 344-348.
60. Moniruzzaman A, Kazanjian A, Wong H, et al. A systematic review on risk factors of mortality among TB patients. Am J Respir Crit Care Med 2010; 181: A5460.
61. El-Sadr WM, Perlman DC, Denning E, et al. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001; 32: 623-632.